If anyone could just use plain old hyaluronidase in reformulating a drug to a subcu version, HALO wouldn't exist as a company. This leaves me wondering what exactly Merck has in their enzyme....
Maybe Merck hopes to extend the patent protection on Keytruda through a novel co-formulation?
Also wondering if Merck could try to use a novel co-formulated product to sidestep a future requirement to negotiate price of Keytruda with Medicare contained in the Inflation Reduction Act?
News 
Market Data 
Discover 
